Controversies in the Treatment of Sepsis

ABSTRACT

Sepsis is a common illness of intensive care unit patients that carries a high morbidity, mortality, and increases hospital cost. Although mortality from sepsis remains high when compared with other critical illnesses, it has declined over the last few decades due to several adjunctive therapies and focused care programs or guidelines. Many interventions, such as early appropriate antibiotic therapy and lung protective, low tidal volume ventilation are commonplace and carry little controversy in their benefit. However, other therapies still have an unclear benefit and remain controversial. This article discusses the controversial roles of intensive insulin therapy, corticosteroids, and activated protein C in the treatment of sepsis.

KEYWORDS

Sepsis - septic shock - activated protein C - insulin - glucose control - corticosteroids

REFERENCES

• 1 Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.  Crit Care Med. 2001;  29 1303-1310
• 2 Woodward B, Cartwright M. Safety of drotrecogin alfa (activated) in severe sepsis: Data from adult clinical trials and observational studies.  J Crit Care. 2009;  24 595-602
• 3 Dellinger R P, Levy M M, Carlet J M International Surviving Sepsis Campaign Guidelines Committee et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.  Crit Care Med. 2008;  36 296-327
• 4 van Ruler O, Schultz M J, Reitsma J B, Gouma D J, Boermeester M A. Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights.  Surg Infect (Larchmt). 2009;  10 339-348
• 5 Byrnes M C, Beilman G J. Adjunctive measures for treating surgical infections and sepsis.  Surg Clin North Am. 2009;  89 349-363, viii
• 6 McCowen K C, Malhotra A, Bistrian B R. Stress-induced hyperglycemia.  Crit Care Clin. 2001;  17 107-124
• 7 Bochicchio G V, Sung J, Joshi M et al.. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients.  J Trauma. 2005;  58 921-924
• 8 Sung J, Bochicchio G V, Joshi M, Bochicchio K, Tracy K, Scalea T M. Admission hyperglycemia is predictive of outcome in critically ill trauma patients.  J Trauma. 2005;  59 80-83
• 9 Laird A M, Miller P R, Kilgo P D, Meredith J W, Chang M C. Relationship of early hyperglycemia to mortality in trauma patients.  J Trauma. 2004;  56 1058-1062
• 10 Jeremitsky E, Omert L A, Dunham C M, Wilberger J, Rodriguez A. The impact of hyperglycemia on patients with severe brain injury.  J Trauma. 2005;  58 47-50
• 11 Griesdale D E, de Souza R J, van Dam R M et al.. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data.  CMAJ. 2009;  180 821-827
• 12 Finfer S, Chittock D R, Su S Y NICE-SUGAR Study Investigators et al. Intensive versus conventional glucose control in critically ill patients.  N Engl J Med. 2009;  360 1283-1297
• 13 van den Berghe G, Wouters P, Weekers F et al.. Intensive insulin therapy in the critically ill patients.  N Engl J Med. 2001;  345 1359-1367
• 14 Van den Berghe G, Wilmer A, Hermans G et al.. Intensive insulin therapy in the medical ICU.  N Engl J Med. 2006;  354 449-461
• 15 Brunkhorst F M, Engel C, Bloos F German Competence Network Sepsis (SepNet) et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis.  N Engl J Med. 2008;  358 125-139
• 16 Preiser J C, Devos P, Ruiz-Santana S et al.. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study.  Intensive Care Med. 2009;  35 1738-1748
• 17 Arabi Y M, Dabbagh O C, Tamim H M et al.. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients.  Crit Care Med. 2008;  36 3190-3197
• 18 Krinsley J S. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients.  Mayo Clin Proc. 2003;  78 1471-1478
• 19 Preiser J C, Devos P. Steps for the implementation and validation of tight glucose control.  Intensive Care Med. 2007;  33 570-571
• 20 Ceriello A, Zarich S W, Testa R. Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting.  J Am Coll Cardiol. 2009;  53(5, Suppl) S9-S13
• 21 Falciglia M, Freyberg R W, Almenoff P L, D'Alessio D A, Render M L. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis.  Crit Care Med. 2009;  37 3001-3009
• 22 Fahy B G, Sheehy A M, Coursin D B. Glucose control in the intensive care unit.  Crit Care Med. 2009;  37 1769-1776
• 23 Inzucchi S E. Clinical practice: management of hyperglycemia in the hospital setting.  N Engl J Med. 2006;  355 1903-1911
• 24 Goldberg P A, Sakharova O V, Barrett P W et al.. Improving glycemic control in the cardiothoracic intensive care unit: clinical experience in two hospital settings.  J Cardiothorac Vasc Anesth. 2004;  18 690-697
• 25 Bilotta F, Caramia R, Cernak I et al.. Intensive insulin therapy after severe traumatic brain injury: a randomized clinical trial.  Neurocrit Care. 2008;  9 159-166
• 26 Bilotta F, Spinelli A, Giovannini F, Doronzio A, Delfini R, Rosa G. The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome, and mortality in neurointensive care unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a randomized prospective pilot trial.  J Neurosurg Anesthesiol. 2007;  19 156-160
• 27 Grey N J, Perdrizet G A. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control.  Endocr Pract. 2004;  10(Suppl 2) 46-52
• 28 He W, Zhang T Y, Zhou H et al.. Impact of intensive insulin therapy on surgical critically ill patients [in Chinese].  Zhonghua Wai Ke Za Zhi. 2007;  45 1052-1054
• 29 Gandhi G Y, Nuttall G A, Abel M D et al.. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial.  Ann Intern Med. 2007;  146 233-243
• 30 Farah R, Samokhvalov A, Zviebel F, Makhoul N. Insulin therapy of hyperglycemia in intensive care.  Isr Med Assoc J. 2007;  9 140-142
• 31 Bland D K, Fankhanel Y, Langford E et al.. Intensive versus modified conventional control of blood glucose level in medical intensive care patients: a pilot study.  Am J Crit Care. 2005;  14 370-376
• 32 Oksanen T, Skrifvars M B, Varpula T et al.. Strict versus moderate glucose control after resuscitation from ventricular fibrillation.  Intensive Care Med. 2007;  33 2093-2100
• 33 Walters M R, Weir C J, Lees K R. A randomised, controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients.  Cerebrovasc Dis. 2006;  22 116-122
• 34 Wiener R S, Wiener D C, Larson R J. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.  JAMA. 2008;  300 933-944
• 35 Vanhorebeek I, Langouche L, Van den Berghe G. Tight blood glucose control with insulin in the ICU: facts and controversies.  Chest. 2007;  132 268-278
• 36 Krinsley J S, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes.  Crit Care Med. 2007;  35 2262-2267
• 37 Dowdy D W, Dinglas V, Mendez-Tellez P A et al.. Intensive care unit hypoglycemia predicts depression during early recovery from acute lung injury.  Crit Care Med. 2008;  36 2726-2733
• 38 Hinshaw L, Peduzzi P, Young E The Veterans Administration Systemic Sepsis Cooperative Study Group et al. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis.  N Engl J Med. 1987;  317 659-665
• 39 Bone R C, Fisher Jr C J, Clemmer T P, Slotman G J, Metz C A, Balk R A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.  N Engl J Med. 1987;  317 653-658
• 40 Bernard G R, Luce J M, Sprung C L et al.. High-dose corticosteroids in patients with the adult respiratory distress syndrome.  N Engl J Med. 1987;  317 1565-1570
• 41 Lefering R, Neugebauer E A. Steroid controversy in sepsis and septic shock: a meta-analysis.  Crit Care Med. 1995;  23 1294-1303
• 42 Annane D, Sébille V, Charpentier C et al.. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
• 43 Sprung C L, Annane D, Keh D CORTICUS Study Group et al. Hydrocortisone therapy for patients with septic shock.  N Engl J Med. 2008;  358 111-124
• 44 Mason P E, Al-Khafaji A, Milbrandt E B, Suffoletto B P, Huang D T. CORTICUS: the end of unconditional love for steroid use?.  Crit Care. 2009;  13 309
• 45 Cuthbertson B H, Sprung C L, Annane D et al.. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock.  Intensive Care Med. 2009;  35 1868-1876
• 46 Annane D, Sébille V, Troché G, Raphaël J C, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.  JAMA. 2000;  283 1038-1045
• 47 Japiassú A M, Salluh J I, Bozza P T, Bozza F A, Castro-Faria-Neto H C. Revisiting steroid treatment for septic shock: molecular actions and clinical effects—a review.  Mem Inst Oswaldo Cruz. 2009;  104 531-548
• 48 Büchele G L, Silva E, Ospina-Tascón G A, Vincent J L, De Backer D. Effects of hydrocortisone on microcirculatory alterations in patients with septic shock.  Crit Care Med. 2009;  37 1341-1347
• 49 Yeager M P, Rassias A J, Pioli P A et al.. Pretreatment with stress cortisol enhances the human systemic inflammatory response to bacterial endotoxin.  Crit Care Med. 2009;  37 2727-2732
• 50 Annane D, Fan E, Herridge M S. Pro-con debate: steroid use in ACTH non-responsive septic shock patients with high baseline cortisol levels.  Crit Care. 2006;  10 210
• 51 Annane D, Bellissant E, Bollaert P E, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis.  BMJ. 2004;  329 480
• 52 Minneci P C, Deans K J, Banks S M, Eichacker P Q, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose.  Ann Intern Med. 2004;  141 47-56
• 53 Balk R A. Steroids for septic shock: back from the dead? (Pro).  Chest. 2003;  123(5, Suppl) 490S-499S
• 54 Cuthill J A, Brett M. The influence of the CORTICUS study on steroid use for septic shock in Scottish intensive care units.  JICS. 2008;  9 238-239
• 55 Groeneveld A B, Molenaar N, Beishuizen B. Should we abandon corticosteroids during septic shock? No.  Curr Opin Crit Care. 2008;  14 384-389
• 56 Hållström L, Berghäll E, Frostell C, Sollevi A, Soop A L. Nitric oxide inhalation and glucocorticoids as combined treatment in human experimental endotoxemia.  Crit Care Med. 2008;  36 3043-3047
• 57 Russell J A, Walley K R, Gordon A C Dieter Ayers for the Vasopressin and Septic Shock Trial Investigators et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock.  Crit Care Med. 2009;  37 811-818
• 58 Ferrer R, Artigas A, Suarez D et al.. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.  Am J Respir Crit Care Med. 2009;  180 861-866
• 59 Minneci P C, Deans K J, Eichacker P Q, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.  Clin Microbiol Infect. 2009;  15 308-318
• 60 Annane D, Bellissant E, Bollaert P E, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock: a systematic review and meta-analysis.  BMJ. 2004;  329 480
• 61 Annane D, Bellissant E, Bollaert P E et al.. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.  JAMA. 2009;  301 2362-2375
• 62 Houston G, Cuthbertson B H. Activated protein C for the treatment of severe sepsis.  Clin Microbiol Infect. 2009;  15 319-324
• 63 Bernard G R, Ely E W, Wright T J et al.. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.  Crit Care Med. 2001;  29 2051-2059
• 64 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 65 Abraham E, Laterre P F, Garg R Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.  N Engl J Med. 2005;  353 1332-1341
• 66 Nadel S, Goldstein B, Williams M D Researching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.  Lancet. 2007;  369 836-843
• 67 Barton P, Kalil A C, Nadel S et al.. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.  Pediatrics. 2004;  113(1 Pt 1) 7-17
• 68 Bernard G R, Margolis B D, Shanies H M Extended Evaluation of Recombinant Human Activated Protein C United States Investigators et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.  Chest. 2004;  125 2206-2216
• 69 Vincent J L, Bernard G R, Beale R et al.. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.  Crit Care Med. 2005;  33 2266-2277
• 70 Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action.  Crit Care. 2007;  11(Suppl 5) S3
• 71 Rowan K M, Welch C A, North E, Harrison D A. Drotrecogin alfa (activated): real-life use and outcomes for the UK.  Crit Care. 2008;  12 R58
• 72 Kanji S, Perreault M M, Chant C, Williamson D, Burry L. Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.  Intensive Care Med. 2007;  33 517-523
• 73 Wheeler A, Steingrub J, Schmidt G A et al.. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.  Crit Care Med. 2008;  36 14-23
• 74 Liu K D, Levitt J, Zhuo H et al.. Randomized clinical trial of activated protein C for the treatment of acute lung injury.  Am J Respir Crit Care Med. 2008;  178 618-623
• 75 Dhainaut J F, Antonelli M, Wright P et al.. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.  Intensive Care Med. 2009;  35 1187-1195
• 76 Vincent J L, Laterre P F, Decruyenaere J et al.. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units—an observational study.  Acta Clin Belg. 2008;  63 25-30
• 77 Martin G, Brunkhorst F M, Janes J M et al.. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.  Crit Care. 2009;  13 R103
• 78 Polli F, Savioli M, Cugno M et al.. Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control.  Minerva Anestesiol. 2009;  75 417-426
• 79 Yan S B, Helterbrand J D, Hartman D L, Wright T J, Bernard G R. Low levels of protein C are associated with poor outcome in severe sepsis.  Chest. 2001;  120 915-922
• 80 Shorr A F, Bernard G R, Dhainaut J F et al.. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome.  Crit Care. 2006;  10 R92
• 81 Finfer S, Ranieri V M, Thompson B T et al.. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.  Intensive Care Med. 2008;  34 1935-1947
• 82 Altaweel L, Sweeney D, Cui X, Barochia A, Natanson C, Qeichacker P. Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.  Biologics. 2009;  3 391-406
• 83 Wiedermann C J, Kaneider N C. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.  BMC Emerg Med. 2005;  5 7
• 84 Laterre P F, Nelson D R, Macias W et al.. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.  J Crit Care. 2007;  22 142-152
• 85 Payen D, Sablotzki A, Barie P S et al.. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.  Surgery. 2007;  141 548-561
• 86 Martí-Carvajal A, Salanti G, Cardona A F. Human recombinant activated protein C for severe sepsis.  Cochrane Database Syst Rev. 2008;  (1) CD004388
• 87 Freeman B D, Zehnbauer B A, Buchman T G. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis.  Shock. 2003;  20 5-9
• 88 Girbes A R, Beishuizen A, Strack van Schijndel R J. Pharmacological treatment of sepsis.  Fundam Clin Pharmacol. 2008;  22 355-361
• 89 Trejnowska E, Popovich M J. Management of sepsis in the ICU.  Int Anesthesiol Clin. 2009;  47 55-66